Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Allergan

Status and phase: Completed; Phase 4

Conditions: Glaucoma; Ocular Hypertension

Treatments: Drug: bimatoprost 0.03% eye drops; Drug: travoprost 0.004% eye drops

Study type: Interventional

Funder types: Industry

Identifiers

NCT00440011

MA-LUM01

Details and patient eligibility

About

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%

Enrollment: 266 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Glaucoma or ocular hypertension in both eyes
• Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering
• Best-corrected visual acuity of 20/100 or better in each eye
• Visual field within 6 months of study entry

Exclusion criteria

• Secondary glaucoma
• Active intraocular inflammation or macular edema
• Intraocular surgery or laser surgery within the past 3 months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

266 participants in 2 patient groups

1

Experimental group

Treatment:

Drug: bimatoprost 0.03% eye drops

2

Active Comparator group

Treatment:

Drug: travoprost 0.004% eye drops